Education
About Us
Working with TipRanks
Follow Us
Oric Pharmaceuticals (ORIC)
NASDAQ:ORIC
ORIC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.90 - $14.67
Previous CloseN/A
Volume181.02K
Average Volume (3M)1.15M
Market Cap
$1.05B
Enterprise Value$513.74M
Total Cash (Recent Filing)$282.51M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Nov 10, 2025EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding97,122,986
10 Day Avg. Volume793,177
30 Day Avg. Volume1,154,058
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.49
Enterprise Value/Revenue481.93
Enterprise Value/Gross Profit-1.47K
Enterprise Value/Ebitda-3.45
Forecast
1Y Price Target
$17.33Price Target Upside59.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Bulls Say, Bears Say
Bulls Say
Analyst RecommendationAnalyst recommends a Buy rating, indicating confidence in ORIC Pharmaceuticals' future performance.
Drug DevelopmentORIC-944 has potentially best-in-class drug properties for the emerging PRC2 inhibitor class for prostate cancer.
Financial PositionThe company's strong cash position, with approximately $436.4 million in cash and investments, supports future development plans.
Bears Say
Clinical Development RisksRisks include inability to advance ORIC-114 and ORIC-944 in clinical development and delays in moving into pivotal trials.
Financial ChallengesFinancial results showed a net loss of $0.47 per share, highlighting ongoing financial challenges.
Safety ConcernsInvestors focused on the safety profile with a high treatment-related Grade ≥3 adverse event rate of 49%.
Oric Pharmaceuticals News
ORIC FAQ
What was Oric Pharmaceuticals’s price range in the past 12 months?
Oric Pharmaceuticals lowest stock price was $3.90 and its highest was $14.67 in the past 12 months.
What is Oric Pharmaceuticals’s market cap?
Oric Pharmaceuticals’s market cap is $1.05B.
When is Oric Pharmaceuticals’s upcoming earnings report date?
Oric Pharmaceuticals’s upcoming earnings report date is Nov 10, 2025 which is in 65 days.
How were Oric Pharmaceuticals’s earnings last quarter?
Oric Pharmaceuticals released its earnings results on Aug 12, 2025. The company reported -$0.47 earnings per share for the quarter, missing the consensus estimate of -$0.443 by -$0.027.
Is Oric Pharmaceuticals overvalued?
According to Wall Street analysts Oric Pharmaceuticals’s price is currently Undervalued.
Does Oric Pharmaceuticals pay dividends?
Oric Pharmaceuticals does not currently pay dividends.
What is Oric Pharmaceuticals’s EPS estimate?
Oric Pharmaceuticals’s EPS estimate is -0.4.
How many shares outstanding does Oric Pharmaceuticals have?
Oric Pharmaceuticals has 97,122,986 shares outstanding.
What happened to Oric Pharmaceuticals’s price movement after its last earnings report?
Oric Pharmaceuticals reported an EPS of -$0.47 in its last earnings report, missing expectations of -$0.443. Following the earnings report the stock price went up 3.256%.
Which hedge fund is a major shareholder of Oric Pharmaceuticals?
Currently, no hedge funds are holding shares in ORIC
Oric Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.33 (59.28% Upside)
$17.33 (59.28% Upside)
Blogger Sentiment
Neutral
ORIC Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 480.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $262.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 17.5%
Last 30 Days ▲ 17.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
12.30%
12-Months-Change
Fundamentals
Return on Equity
-43.82%
Trailing 12-Months
Asset Growth
5.46%
Trailing 12-Months
Company Description
Oric Pharmaceuticals
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
ORIC Stock 12 Month Forecast
Average Price Target
$17.33
▲(59.28% Upside)
Technical Analysis
Celcuity
―
Checkpoint Therapeutics
―
Autolus Therapeutics
―
Sana Biotechnology
―
Erasca
―
Ownership Overview
6.55% Insiders
10.74% Mutual Funds
0.10% Other Institutional Investors
74.91% Public Companies and
Individual Investors